Lina Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lina Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Chunyan Lei
Department of Ophthalmology, and Research Laboratory of Macular Disease, West China Hospital Sichuan University Chengdu China
1 shared publication- Hongmei Luo
Innovative Institute of Chinese Medicine and Pharmacy Chengdu University of Traditional Chinese Medicine Chengdu China
1 shared publication Jinnan Liu
Innovative Institute of Chinese Medicine and Pharmacy Chengdu University of Traditional Chinese Medicine Chengdu China
1 shared publication- Meixia Zhang
Sichuan University
1 shared publication - Shiqi Li
Innovative Institute of Chinese Medicine and Pharmacy Chengdu University of Traditional Chinese Medicine Chengdu China
1 shared publication - Xi Huang
Department of Ophthalmology and Research Laboratory of Macular Disease, West China Hospital, Sichuan University, Chengdu 610041, China
1 shared publication
Latest Publications
- Open Access
- 31 July 2024
- Published by Wiley in Cell Proliferation
- Vol. 57 (11) , e13695
Therapeutic effects of tetrahedral framework nucleic acids and tFNAs‐miR22 on retinal ischemia/reperfusion injury
Retinal ischemia/reperfusion injury (RI/R) is a common pathological process in ophthalmic diseases, which can cause severe visual impairment. The mechanisms underlying RI/R damage and repair are still unclear. Scholars are actively exploring effective intervention strategies to restore impaired visual function. With the development of nucleic acid nanomaterials, tetrahedral framework nucleic acids (tFNAs) have shown promising therapeutic potential in various fields such as stem cells, biosensors, and tumour treatment due to their excellent biological properties. Besides, miRNA‐22‐3p (miR‐22), as an important regulatory factor in neural tissue, has been proven to have positive effects in various neurodegenerative diseases. By stably constructing a complex of tetrahedral framework nucleic acids miR22 (tFNAs‐miR22), we observed that tFNAs‐miR22 had a positive effect on the repair of RI/R injury in retinal neural tissue. Previous studies have shown that tFNAs can effectively deliver miR‐22 into damaged retinal neurons, subsequently exerting neuroprotective effects. Interestingly, we found that there was a certain synergistic effect between tFNAs and miR‐22. tFNAs‐miR22 can selectively activated the ERK1/2 signalling pathway to reduce neuronal apoptosis, accelerate cell proliferation, and restore synaptic functional activity. In this study, we established a simple yet effective small molecule drug for RI/R treatment which may become a promising neuroprotectant for treating this type of vision impairment disease in the future.
- 31 July 2024
- Published by Wiley in Cell Proliferation
- Vol. 57 (11) , e13695
Open AccessTherapeutic effects of tetrahedral framework nucleic acids and tFNAs‐miR22 on retinal ischemia/reperfusion injury
Retinal ischemia/reperfusion injury (RI/R) is a common pathological process in ophthalmic diseases, which can cause severe visual impairment. The mechanisms underlying RI/R damage and repair are still unclear. Scholars are actively exploring effective intervention strategies to restore impaired visual function. With the development of nucleic acid nanomaterials, tetrahedral framework nucleic acids (tFNAs) have shown promising therapeutic potential in various fields such as stem cells, biosensors, and tumour treatment due to their excellent biological properties. Besides, miRNA‐22‐3p (miR‐22), as an important regulatory factor in neural tissue, has been proven to have positive effects in various neurodegenerative diseases. By stably constructing a complex of tetrahedral framework nucleic acids miR22 (tFNAs‐miR22), we observed that tFNAs‐miR22 had a positive effect on the repair of RI/R injury in retinal neural tissue. Previous studies have shown that tFNAs can effectively deliver miR‐22 into damaged retinal neurons, subsequently exerting neuroprotective effects. Interestingly, we found that there was a certain synergistic effect between tFNAs and miR‐22. tFNAs‐miR22 can selectively activated the ERK1/2 signalling pathway to reduce neuronal apoptosis, accelerate cell proliferation, and restore synaptic functional activity. In this study, we established a simple yet effective small molecule drug for RI/R treatment which may become a promising neuroprotectant for treating this type of vision impairment disease in the future.